A Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy and Sfaety of PF-04236921 in subjects with Crohn's Disease Who are Anti-TNF Inadequate Responders

Grants and Contracts Details

StatusFinished
Effective start/end date8/12/1112/31/15

Funding

  • Pfizer Inc.: $42,690.00